Impact of Branded versus Generic Drug Use in Chronic Disease Management in Hong Kong – Healthcare Professionals’ and Public’s Perspectives

Lee VW¹, Cheng FW¹
¹ School of Pharmacy, Chinese University of Hong Kong, Shatin, Hong Kong SAR

Background

Significant increment of healthcare expenditure

Generic substitution saves \$\$\$

Common practice around the world – either mandatory or voluntary

?Do Hong Kong people accept generic substation?

Methodology

Nature: Cross-sectional descriptive study
Tools: Self-completed anonymous questionnaire
Recruitment Period: Mar 2015 to May 2017
Target: General Public, Doctors, Pharmacists, Nurses

Questionnaire

References

1. Facts About Generic Drugs. <https://www.fda.gov/downloads/drugs/resourcesforconsumers/buyingsafely/understandinggenericdrugs/ucm305908.pdf>. Accessed August 25, 2017.
2. King DR, Kanavos P. Encouraging the use of generic medicines: implications for transition economies. *Croat Med J*. 2002;43(4):462-469. <http://www.ncbi.nlm.nih.gov/pubmed/12187525>. Accessed August 25, 2017.
3. Our 5 pillars | Medicines for Europe. <http://www.medicinesforeurope.com/generic-medicines/our-5-pillars/>. Accessed August 25, 2017.
4. Hospital Authority's Drug Management. Hong Kong; 2016. http://www.aud.gov.hk/pdf_e/e67d0d5.pdf. Accessed October 3, 2017.
5. Chong CP, March G, Clark A, Gilbert A, Hassall MA, Bahari MB. A nationwide study on generic medicines substitution practices of Australian community pharmacists and patient acceptance. *Health Policy (New York)*. 2011;99(2):139-148. doi: 10.1016/j.healthpol.2010.08.002.
6. Kobayashi E, Karigome H, Sakurada T, Satoh N, Ueda S. Patients' attitudes towards generic drug substitution in Japan. *Health Policy (New York)*. 2011;99(1):60-65. doi:10.1016/j.healthpol.2010.07.006.
7. Andersson K, Sonesson C, Petzold M, Carlsten A, Lönnroth K. What are the obstacles to generic substitution? An assessment of the behaviour of prescribers, patients and pharmacies during the first year of generic substitution in Sweden. *Pharmacoepidemiol Drug Saf*. 2005;14(5):341-348. doi:10.1002/pds.1055.
8. Himmel W, Simmenroth-Nayda A, Niebling W, et al. What do primary care patients think about generic drugs? *Int J Clin Pharmacol Ther*. 2005;43(10):472-479. <http://www.ncbi.nlm.nih.gov/pubmed/16240704>. Accessed August 25, 2017.
9. Ioannescu A, Halm EA, McGinn T, Su AL, Federman AD. Beliefs about generic drugs among elderly adults in hospital-based primary care practices. *Patient Educ Couns*. 2008;73(2):377-383. doi:10.1016/j.pec.2008.07.012.
10. Kjønniksen J, Lindbaek M, Granes AG. Patients' attitudes towards and experiences of generic drug substitution in Norway. *Pharm World Sci*. 2006;28(5):284-289. doi:10.1007/s11096-006-9043-5.
11. Babar Z-U-D, Grover P, Stewart J, et al. Evaluating pharmacists' views, knowledge, and perception regarding generic medicines in New Zealand. *Res Soc Adm Pharm*. 2011;7(3):294-305. doi:10.1016/j.sapharm.2010.06.004.
12. Rodríguez-Cavillo JA, Lana A, Cueto A, Martham WA, López ML. Psychosocial factors associated with the prescription of generic drugs. *Health Policy (New York)*. 2011;101(2):176-184. doi:10.1016/j.healthpol.2010.10.015.
13. Privitera MD, Welty TE, Gidal BE, et al. Generic-to-generic lamotrigine switches in people with epilepsy: the randomised controlled EQUIGEN trial. *Lancet Neurol*. 2016;15(4):365-372. doi:10.1016/S1474-4422(16)00014-4.
14. Ting TY, Jang W, Lönnerberg R, et al. Generic lamotrigine versus brand-name lamotrigine in patients with epilepsy: A field test of the FDA bioequivalence standard. *Epilepsia*. 2015;56(9):1415-1424. doi:10.1111/epi.13095.
15. Williamson J, Reid A, Monie RD, Fennerty AG, Rimmer DM. Generic inhaled salbutamol versus branded salbutamol: A randomised double-blind study. *Postgrad Med J*. 1997;73(857):156-158. <http://www.ncbi.nlm.nih.gov/pubmed/9135831>. Accessed August 25, 2017.
16. Report of the Review Committee on Regulation of Pharmaceutical Products in Hong Kong; 2009. http://www.fhb.gov.hk/download/press_and_publications/otherinfo/100105_pharm_review/en_full_report.pdf. Accessed August 25, 2017.
17. Guidance for Industry Bioavailability and Bioequivalence Studies for Orally Administered Drug Products – General Considerations. 2003;301-827. <http://www.fda.gov/cder/guidance/index.htm>. Accessed October 3, 2017.
18. New Zealand Regulatory Guidelines for Medicines Part A: When is an application for approval of a new or changed medicine required? 2014. <http://www.medsafe.govt.nz/regulatory/Guideline/Ful - NZ Regulatory Guidelines for Medicines.pdf>. Accessed October 3, 2017.
19. Implementation Plan of Phase 2 Requirement of Bioavailability and Bioequivalence Studies for the Registration of Generic Drugs; 2016. http://drugoffice.gov.hk/eps/upload/eps_news/26420/EN/1/Letter%20to%20Trade%20-%20Implementation%20Plan%20of%20Phase%20of%20Requirement_v.5.pdf. Accessed August 25, 2017.
20. Chua GN, Hassall MB, Shafie AK, Awaisu A. A survey exploring knowledge and perceptions of general practitioners towards the use of generic medicines in the northern state of Malaysia. *Health Policy (New York)*. 2010;95(2-3):229-235. doi: 10.1016/j.healthpol.2009.11.019.

Results

	General Public	Physicians	Nurse	Pharmacist
N	2106	73	22	50
Male Gender	738 (35.0%)	47 (64.3%)	4 (18.2%)	21 (42.0%)
Top Three Factors For Generic Substitution				
1st	Efficacy	Efficacy	Efficacy	Efficacy
2nd	Advice from HCP	S/E Profiles	S/E Profiles	Price
3rd	S/E Profiles	Price	Price	S/E Profiles
Views on Policy				
Voluntary Substitution	50.0%	42.5%	63.6%	92.0%
Patients' Consent	69.1%	11.0%	18.2%	34.0%

HCP: Healthcare Professionals; S/E: Side Effects

Conclusions

- Insufficient knowledge about generic drugs in both public and healthcare professionals
- Patient Consent Prior to Substitution: Controversies among Different Stakeholders